Drug for anemic cancer patients raises ris...(a previously known 57 percent increased ...),Health
Navigation Links
Drug for anemic cancer patients raises risk of death
Date:2/26/2008
a previously known 57 percent increased risk of blood clots in the legs or lungs for cancer patients receiving ESAs. But the higher blood clot risk did not explain the 10 percent increased risk of death shown in his study, Bennett said.
"We know that ESA's may prevent a blood transfusion, but if I had cancer and I needed a blood transfusion, I would be much more conservative about taking ESAs," Bennett said. "The current FDA recommendation is these drugs are safe for cancer patients as long their hemoglobin levels aren't raised too high. Our data do not support that."
Lai cautioned that various solid tumors such as breast cancer, colon cancer and melanoma may react differently to ESAs. "The exact effect and size of that effect may be different depending upon the type of tumor. Additional research is clearly necessary, and we have to be careful about generalizing these results before further research is conducted," he said.
On March 13, the FDA's Oncologic Drugs Advisory Committee will meet in Gaithersburg, Md. to discuss the cumulative data, including the recent study results, regarding the use of ESAs for cancer patients, Bennett said.
'/>"/>
| Contact: Marla Paul Marla-Paul@northwestern.edu 312-503-8928 Northwestern University Source:Eurekalert |
Related medicine news :
1. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
2. Researchers identify and shut down protein that fuels ovarian cancer
3. Anemia Drugs for Cancer Patients Increase Death Risk
4. Hall of Fame Shortstop Cal Ripken, Jr. Renews Commitment to Lung Cancer
5. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
6. Study looks at new bladder cancer therapy for patients unresponsive to standard treatment
7. Enormous Progress in Reducing Cancer Does Not Include Lung Cancer
8. FSU College of Medicine researcher seeks to uncover new cancer therapies
9. OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer
10. Test can reduce recurrence of breast cancer
11. Study details link between obesity, carbs and esophageal cancer
Post Your Comments:
(Date:12/4/2008)... SEATTLE, Dec. 5 Cell T...q and MTA: CTIC) today announced that that its Boa...Auction" tender offer to,purchase a portion or al...) as,follows: , , -- 4% Convertible Senior...ible Senior Notes due 2011, -- 6.75% Convertib...
(Date:12/4/2008)... , Patients with idiopathic pulmonary fibrosis (I... coronary eventsincluding heart attacksthan people...that analyzed the risk of cardiovascular disease i...00 matched controls. , "If you look at them over...ncreased risk of acute coronary syndrome, which is...
(Date:12/4/2008)... , Early detection of lung disease in cystic fibr...nfants, may be the key to controlling the progress...ew research shows that contrary to previous scient...ts can begin as early as infancy even though lung ...We might be able to stop some of the lung function...
(Date:12/4/2008)... NEW DELHI, India, Dec. 5 /PRNewswire-USNewswire/... Organization today launched a global partnership ...afer, accurate and affordable alternatives. , ...he South Asian Conference on Alternatives to Mercu...rganizations and the Indian NGO Toxics Link. , ...
Breaking Medicine News(10 mins):Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 2Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 3Health News:Double threat: Deadly lung disease also linked to heart attacks 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2[0] Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes[0] Double threat: Deadly lung disease also linked to heart attacks[0] Intervention in infants with cystic fibrosis key to slowing progression[0] Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices
...ave been able to generate human skin tissues, whic...ncer//. The researchers for the study feel that th...enic potential of genes in development of skin can...f skin cancer that results from the cells called m...
...rom University of Liverpool had proposed that pati...efit from medication.// They say that it is advisa...ileptic patients. Researchers of the study feel th...gnificantly benefit the patients in having a bette...
...eating HIV/AIDS patients with highly active antire...f the cardiac risks involved, says researchers fro...can dramatically improve the quality of a HIV/AIDS...specially helpful for patients with advanced HIV-1...
...suffering from head and neck cancer who are underg...edication to fight oropharyngeal candidiasis. Orop... mouth caused by the yeast Candida. This condition... of the disease are the formation of white plaques...
Other Medicine News:(Date:12/4/2008)... PARK, Calif., Dec. 4 Long-term da...expected decrease in Mitral Vale Area (MVA),after...tral regurgitation (MR),is not associated with cl...,with two years of follow-up, none of the patien...surgery for mitral stenosis. At 12 months no,impo...
(Date:12/3/2008)...igna front-line data demonstrating potential in ne...e of leukemia to be featured in two oral sessions ...benefits for chronically transfused patients by si...y organs , , - New long-term data from majo...rt on optimal post-surgery treatment strategy, Fem...
(Date:12/3/2008)...GEVILLE, Pa., Dec. 3 Wye...WYE ), announced today that it has submitted a,ma...opean Medicines Agency,(EMEA) for approval to mar...njugate vaccine (PCV13) for infants and young chil...vention of pneumococcal disease (PD) caused by the...
(Date:12/2/2008)...GO, Dec. 3 Researchers ...the circuitry in the area of the brain,responsibl...nts suffering from,stress-related psychiatric dis...day at the annual meeting of the Radiological Soci...ts with major depression and other stress-related ...
Breaking Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 1Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 3Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 1Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 1Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 3Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 1Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 2Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 3Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 5Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 6[0] Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System[0] More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies[0] Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children[0] Stress-Related Disorders Affect Brain's Processing of Memory
...1, 2007--Researchers report that a,variation in a ...isk and that this common variation may be responsi...in white men in the United States.,The research wa...cer Institute (NCI), part of the National Institut...etic Markers of Susceptibility,(CGEMS) initiative....
...INESS WIRE)--Apr 3, 2007 - Calando,Pharmaceuticals...ity-owned subsidiary of Arrowhead Research Corpora...study demonstrating,the anti-proliferative effect ...component of its lead anti-cancer compound, CALAA-...of Ribonucleotide,Reductase Subunit RRM2 Reduce Ce...
Other Medicine Technology:Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 2Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 3Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 4Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate 2Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate 3Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate 4...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |